Lara S Shekerdemian1, Nabihah R Mahmood2, Katie K Wolfe3, Becky J Riggs4, Catherine E Ross5, Christine A McKiernan6, Sabrina M Heidemann7, Lawrence C Kleinman8, Anita I Sen9, Mark W Hall10, Margaret A Priestley11, John K McGuire12, Konstantinos Boukas13, Matthew P Sharron14, Jeffrey P Burns5. 1. Texas Children's Hospital, Baylor College of Medicine, Houston. 2. Children's Healthcare of Atlanta, Atlanta, Georgia. 3. Ann and Robert H. Lurie Children's Hospital, Northwestern University Feinberg School of Medicine, Chicago, Illinois. 4. Johns Hopkins Children's Center, Johns Hopkins School of Medicine, Baltimore, Maryland. 5. Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts. 6. Baystate Children's Hospital, UMass Medical School Baystate Campus, Springfield, Massachusetts. 7. Children's Hospital of Michigan, Wayne State University, Detroit. 8. Bristol-Myers Squibb Hospital, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, New Jersey. 9. NewYork-Presbyterian Morgan Stanley Children's Hospital, Columbia University Medical Center, New York. 10. Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus. 11. Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia. 12. Seattle Children's Hospital, University of Washington, Seattle. 13. Children's Memorial Hermann Hospital, University of Texas, Houston. 14. Children's National Medical Center, George Washington School of Medicine, Washington, DC.
Abstract
IMPORTANCE: The recent and ongoing coronavirus disease 2019 (COVID-19) pandemic has taken an unprecedented toll on adults critically ill with COVID-19 infection. While there is evidence that the burden of COVID-19 infection in hospitalized children is lesser than in their adult counterparts, to date, there are only limited reports describing COVID-19 in pediatric intensive care units (PICUs). OBJECTIVE: To provide an early description and characterization of COVID-19 infection in North American PICUs, focusing on mode of presentation, presence of comorbidities, severity of disease, therapeutic interventions, clinical trajectory, and early outcomes. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study included children positive for COVID-19 admitted to 46 North American PICUs between March 14 and April 3, 2020. with follow-up to April 10, 2020. MAIN OUTCOMES AND MEASURES: Prehospital characteristics, clinical trajectory, and hospital outcomes of children admitted to PICUs with confirmed COVID-19 infection. RESULTS: Of the 48 children with COVID-19 admitted to participating PICUs, 25 (52%) were male, and the median (range) age was 13 (4.2-16.6) years. Forty patients (83%) had significant preexisting comorbidities; 35 (73%) presented with respiratory symptoms and 18 (38%) required invasive ventilation. Eleven patients (23%) had failure of 2 or more organ systems. Extracorporeal membrane oxygenation was required for 1 patient (2%). Targeted therapies were used in 28 patients (61%), with hydroxychloroquine being the most commonly used agent either alone (11 patients) or in combination (10 patients). At the completion of the follow-up period, 2 patients (4%) had died and 15 (31%) were still hospitalized, with 3 still requiring ventilatory support and 1 receiving extracorporeal membrane oxygenation. The median (range) PICU and hospital lengths of stay for those who had been discharged were 5 (3-9) days and 7 (4-13) days, respectively. CONCLUSIONS AND RELEVANCE: This early report describes the burden of COVID-19 infection in North American PICUs and confirms that severe illness in children is significant but far less frequent than in adults. Prehospital comorbidities appear to be an important factor in children. These preliminary observations provide an important platform for larger and more extensive studies of children with COVID-19 infection.
IMPORTANCE: The recent and ongoing coronavirus disease 2019 (COVID-19) pandemic has taken an unprecedented toll on adults critically ill with COVID-19 infection. While there is evidence that the burden of COVID-19 infection in hospitalized children is lesser than in their adult counterparts, to date, there are only limited reports describing COVID-19 in pediatric intensive care units (PICUs). OBJECTIVE: To provide an early description and characterization of COVID-19 infection in North American PICUs, focusing on mode of presentation, presence of comorbidities, severity of disease, therapeutic interventions, clinical trajectory, and early outcomes. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study included children positive for COVID-19 admitted to 46 North American PICUs between March 14 and April 3, 2020. with follow-up to April 10, 2020. MAIN OUTCOMES AND MEASURES: Prehospital characteristics, clinical trajectory, and hospital outcomes of children admitted to PICUs with confirmed COVID-19 infection. RESULTS: Of the 48 children with COVID-19 admitted to participating PICUs, 25 (52%) were male, and the median (range) age was 13 (4.2-16.6) years. Forty patients (83%) had significant preexisting comorbidities; 35 (73%) presented with respiratory symptoms and 18 (38%) required invasive ventilation. Eleven patients (23%) had failure of 2 or more organ systems. Extracorporeal membrane oxygenation was required for 1 patient (2%). Targeted therapies were used in 28 patients (61%), with hydroxychloroquine being the most commonly used agent either alone (11 patients) or in combination (10 patients). At the completion of the follow-up period, 2 patients (4%) had died and 15 (31%) were still hospitalized, with 3 still requiring ventilatory support and 1 receiving extracorporeal membrane oxygenation. The median (range) PICU and hospital lengths of stay for those who had been discharged were 5 (3-9) days and 7 (4-13) days, respectively. CONCLUSIONS AND RELEVANCE: This early report describes the burden of COVID-19 infection in North American PICUs and confirms that severe illness in children is significant but far less frequent than in adults. Prehospital comorbidities appear to be an important factor in children. These preliminary observations provide an important platform for larger and more extensive studies of children with COVID-19 infection.
Authors: Pavan K Bhatraju; Bijan J Ghassemieh; Michelle Nichols; Richard Kim; Keith R Jerome; Arun K Nalla; Alexander L Greninger; Sudhakar Pipavath; Mark M Wurfel; Laura Evans; Patricia A Kritek; T Eoin West; Andrew Luks; Anthony Gerbino; Chris R Dale; Jason D Goldman; Shane O'Mahony; Carmen Mikacenic Journal: N Engl J Med Date: 2020-03-30 Impact factor: 91.245
Authors: Simona Di Giambenedetto; Arturo Ciccullo; Alberto Borghetti; Giovanni Gambassi; Francesco Landi; Elena Visconti; Lorenzo Zileri Dal Verme; Roberto Bernabei; Enrica Tamburrini; Roberto Cauda; Antonio Gasbarrini Journal: J Med Virol Date: 2020-06-29 Impact factor: 20.693
Authors: María Ríos-Barnés; Miguel Lanaspa; Antoni Noguera-Julian; Laia Baleta; Mariona Fernández De Sevilla; David Ferri; Julià Götzens; Iolanda Jordan; Laura Lecina; Laura Monfort; María Trabazo; Eneritz Velasco-Arnaiz; Isabel Badell; Clàudia Fortuny; Victòria Fumadó Journal: Arch Bronconeumol Date: 2020-09-19 Impact factor: 4.872
Authors: Pui Y Lee; Megan Day-Lewis; Lauren A Henderson; Kevin G Friedman; Jeffrey Lo; Jordan E Roberts; Mindy S Lo; Craig D Platt; Janet Chou; Kacie J Hoyt; Annette L Baker; Tina M Banzon; Margaret H Chang; Ezra Cohen; Sarah D de Ferranti; Audrey Dionne; Saddiq Habiballah; Olha Halyabar; Jonathan S Hausmann; Melissa M Hazen; Erin Janssen; Esra Meidan; Ryan W Nelson; Alan A Nguyen; Robert P Sundel; Fatma Dedeoglu; Peter A Nigrovic; Jane W Newburger; Mary Beth F Son Journal: J Clin Invest Date: 2020-11-02 Impact factor: 14.808
Authors: Lauren A Henderson; Scott W Canna; Kevin G Friedman; Mark Gorelik; Sivia K Lapidus; Hamid Bassiri; Edward M Behrens; Anne Ferris; Kate F Kernan; Grant S Schulert; Philip Seo; Mary Beth F Son; Adriana H Tremoulet; Rae S M Yeung; Amy S Mudano; Amy S Turner; David R Karp; Jay J Mehta Journal: Arthritis Rheumatol Date: 2021-02-15 Impact factor: 10.995
Authors: Giuseppe Indolfi; Micol Stivala; Matteo Lenge; Ruben Diaz Naderi; Jennifer McIntosh; Ricard Casadevall Llandrich; Joe Gannon; Kathleen S McGreevy; Sandra Trapani; Päivi Miettinen; Pekka Lahdenne; Louisa Desborough; Jana Pavare; Annemarie van Rossum; Dagmara Zyska; Massimo Resti; Alberto Zanobini Journal: Front Public Health Date: 2021-04-26
Authors: Abeer A Alnajjar; Ahmed M Dohain; Gaser A Abdelmohsen; Turki S Alahmadi; Zaher F Zaher; Abobakr A Abdelgalil Journal: Saudi Med J Date: 2021-04 Impact factor: 1.484